Thursday, 15 October, 2026
AI Meets Oncology: AstraZeneca Inks $40M Deal with insitro to Accelerate Drug Discovery
By TechShots Studio
AstraZeneca has partnered with South San Francisco-based insitro in a deal valued up to $40 million to accelerate AI-driven drug discovery for oncology and rare diseases. The collaboration leverages insitro’s proprietary machine learning platform and high-throughput biological data to identify novel targets and optimize therapeutic molecules, aiming to significantly shorten development timelines for life-saving treatments.
Read full story at REUTERS